Press Release May 21, 2020

HotSpot Therapeutics Completes $65 Million Series B

The Life Sciences team advised HotSpot Therapeutics on the completion of its $65 million Series B financing. The financing round was led by S.R. One, Limited and included funds managed by Tekla Capital Management, MRL Ventures Fund, Solasta Ventures and Brace Pharma (via affiliate Cleva Pharma), along with co-founding investors Atlas Venture and Sofinnova Partners. 

The Series B financing will support the advancement of HotSpot’s lead programs to the clinic, including protein kinase C (PKC-theta) antagonists for Th2 and T-reg driven autoimmune disease and S6 kinase (S6K) antagonists for rare metabolic disease. The financing will also accelerate the discovery-stage pipeline targeting genetically validated transcription factors and E3 ligases, including CBL-B.

HotSpot is targeting nature’s regulatory mechanisms to create allosteric medicines that exhibit high precision and potency. The company leverages its proprietary SpotFinder™ technology, the first and only platform designed to identify and target “regulatory hotspots,” a unique family of pockets that sit remote from the active site on a protein and are used by nature to control protein function. 

The Goodwin team was led by William Collins, Katherine Maxwell, Kimberly Larie and Joshua Tarr and included Jacob Osborn and Rick Kline with invaluable assistance from Coleen Doyle. 

For additional details on the financing, please read the press release.